Johnson & Johnson Supports HRS Registry to Enhance Real-World Evidence for PFA
ohnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced its sponsorship of a new data collection platform developed by the Heart Rhythm Society (HRS) to capture real-world data on pulsed field ablation (PFA) procedures used to treat atrial fibrillation (AFib). The first-of-its-kind registry will serve as a long-term data collection platform to evaluate clinical outcomes, support evidence-based practice, and inform the evolution of treatment strategies in electrophysiology.
“We’re sponsoring this registry to enable real-world data generation at scale across the industry to shape the future of AFib ablation. By complementing our own evidence-generation registries and studies with this data platform, we aim to shape best practices, guide continued innovation and ultimately improve outcomes for more people living with AFib,” said Michael Bodner, Company Group Chair, Electrophysiology & Neurovascular, MedTech. “This effort reflects our long-standing commitment to partnering with the clinical community and strengthening scientific understanding, a dedication grounded in our decades of scientific expertise and leadership in electrophysiology.”
Johnson & Johnson MedTech is committed to advancing the science of PFA and driving progress in arrythmia care, building on our leadership and an unwavering dedication to enhance healthcare through rigorous scientific inquiry and clinical excellence in electrophysiology. This commitment is reflected in our comprehensive, fully integrated portfolio of imaging, mapping, and ablation technologies -including versatile PFA platforms- designed to deliver safe, precise, and consistent outcomes to support procedures across a wide range of patient needs.
Cardiovascular Solutions from Johnson & Johnson MedTech
Across, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration, and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more, visit biosensewebster.com.
About Johnson & Johnson
At , we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.
Source Link: https://www.jnj.com/
